As pharmaceutical companies strive to develop safer medicines at a lower cost they must keep pace with the rapid growth of technology and research methodologies. Defying the misconception of process chemistry as mere scale-up work Process Chemistry in the Pharmaceutical Industry Vol. 2: Challenges in an Ever Changing Climate explores novel applications of synthetic physical and analytical chemistry in drug discovery and development. It offers an accurate depiction of the most up-to-date process research and development methods applied to synthesis clinical trials and commercializing drug candidates. The second installment in this progressive series this volumereviews the latest breakthroughs to advance process chemistry including asymmetric synthesis crystallization morphology enzymatic intervention green chemistry macromolecules (monoclonal antibodies biological molecules polymers) enantioselectivity organometallic chemistry process analytical tools chemical engineering controls regulatory compliance and outsourcing/globalization. It explores new approaches to synthetic processes examines the latest safety methods and experiment design and suggests realistic solutions to problems encountered in manufacturing and process development. Significant topics include atom economy ease of synthesis instrumentation automization quality control cost considerations green practices and future trends. Jointly edited by the founder/president of Delphian Pharmaceuticals and the director of Chemical R&D at Pfizer this book brings together contributions byreputed scientists technologists engineers and professors from leading academic institutions such as the Imperial College UK the University of Tokyo ETH Switzerland the International University at Bermen Germany and the University of Connecticut USA and from principal pharmaceutical companies that include Merck Bristol Myers Squibb Pfizer Novartis Eli Lilly Astrazeneca and DSM. | Process Chemistry in the Pharmaceutical Industry Volume 2 Challenges in an Ever Changing Climate